Literature DB >> 12649710

Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in hematologic patients in a single cancer center.

E Velasco1, R Byington, C A S Martins, M Schirmer, L M C Dias, V M S C Gonçalves.   

Abstract

Bloodstream infections (BSIs) have an important impact on the outcome of cancer patients. A prospective cohort study was undertaken at a referral cancer center in order to describe the clinical and microbiological characteristics of patients with hematologic malignancies and BSIs and to identify independent predictors associated with mortality. The study enrolled 110 consecutive BSI episodes during an 18-month period. Patients were monitored for 30 days after the last positive blood culture. There were 10.24 BSI episodes per 1,000 patient-days. The median age of the patients was 25 years. Most patients had acute leukemia ( n=72). The origin of the BSI was unknown in 43.6% of the episodes and was associated with known sites in 32.7%. There were 58 concomitant infectious sites (lungs, 43%, and soft tissue, 22.4%) and 195 noninfectious comorbid factors (poor performance status, 30.2%; undernourishment, 14.3%). The median neutrophil count was 215 cells/mm(3). Indwelling catheters were present in 70% of the episodes. The majority of isolates obtained within the first 48 h of the BSI episode (61%) were gram-negative rods. Overall mortality was 24.5%. Multivariate analysis using logistic regression showed relapsed leukemia, poor performance status, recent weight loss, and ventilatory failure requiring ventilatory support as independent predictors of mortality. Hematologic cancer patients with BSIs should be regarded as a distinct group of patients at high risk of death. The knowledge of variables amenable to intervention would help diminish or prevent serious medical complications.

Entities:  

Mesh:

Year:  2003        PMID: 12649710     DOI: 10.1007/s10096-003-0894-6

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  30 in total

1.  Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia.

Authors:  B Byl; P Clevenbergh; F Jacobs; M J Struelens; F Zech; A Kentos; J P Thys
Journal:  Clin Infect Dis       Date:  1999-07       Impact factor: 9.079

2.  Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program.

Authors:  A Cometta; T Calandra; H Gaya; S H Zinner; R de Bock; A Del Favero; G Bucaneve; F Crokaert; W V Kern; J Klastersky; I Langenaeken; A Micozzi; A Padmos; M Paesmans; C Viscoli; M P Glauser
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Rising incidence of Candida parapsilosis fungemia in patients with hematologic malignancies: clinical aspects, predisposing factors, and differential pathogenicity of the causative strains.

Authors:  C Girmenia; P Martino; F De Bernardis; G Gentile; M Boccanera; M Monaco; G Antonucci; A Cassone
Journal:  Clin Infect Dis       Date:  1996-09       Impact factor: 9.079

4.  Pulmonary infiltrates in adult acute leukaemia: empirical treatment or lung biopsy?

Authors:  A G Wardman; N J Cooke
Journal:  Thorax       Date:  1984-09       Impact factor: 9.139

5.  Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution.

Authors:  E González-Barca; A Fernández-Sevilla; J Carratalá; A Grañena; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

6.  An outbreak of Acinetobacter baumannii: the importance of cross-transmission.

Authors:  E M D'Agata; V Thayer; W Schaffner
Journal:  Infect Control Hosp Epidemiol       Date:  2000-09       Impact factor: 3.254

7.  Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials.

Authors:  L S Elting; E B Rubenstein; K V Rolston; G P Bodey
Journal:  Clin Infect Dis       Date:  1997-08       Impact factor: 9.079

8.  Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality.

Authors:  D Pittet; D Tarara; R P Wenzel
Journal:  JAMA       Date:  1994-05-25       Impact factor: 56.272

Review 9.  Importance of Candida species other than C. albicans as pathogens in oncology patients.

Authors:  J R Wingard
Journal:  Clin Infect Dis       Date:  1995-01       Impact factor: 9.079

View more
  8 in total

1.  Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure.

Authors:  Federico Pea; Pierluigi Viale; Daniela Damiani; Federica Pavan; Francesco Cristini; Renato Fanin; Mario Furlanut
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

2.  Comparative study of clinical characteristics of neutropenic and non-neutropenic adult cancer patients with bloodstream infections.

Authors:  E Velasco; R Byington; C A S Martins; M Schirmer; L M C Dias; V M S C Gonçalves
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-01       Impact factor: 3.267

3.  Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters.

Authors:  H Syrjälä; P Ohtonen; U Kinnunen; R Räty; E Elonen; T Nousiainen; E Jantunen; K Remes; M Itälä-Remes; R Silvennoinen; P Koistinen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-17       Impact factor: 3.267

4.  Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in adult surgical cancer patients.

Authors:  E Velasco; M Soares; R Byington; C A S Martins; M Schirmer; L M C Dias; V M S Gonçalves
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-28       Impact factor: 3.267

5.  Incidence and management of infections in patients with acute leukemia following chemotherapy in general wards.

Authors:  Sasmita Biswal; Chaitali Godnaik
Journal:  Ecancermedicalscience       Date:  2013-04-22

6.  Bloodstream infections in patients with or without cancer in a large community hospital.

Authors:  M M E M Bos; L S Smeets; I Dumay; E de Jonge
Journal:  Infection       Date:  2013-05-05       Impact factor: 3.553

Review 7.  Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams.

Authors:  Mical Paul; Dafna Yahav; Assaf Bivas; Abigail Fraser; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

8.  Modulation of macrophage cytokine profiles during solid tumor progression: susceptibility to Candida albicans infection.

Authors:  Marcela R Camargo; James Venturini; Fátima R Vilani-Moreno; Maria Sueli P Arruda
Journal:  BMC Infect Dis       Date:  2009-06-17       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.